Figure 3, [Epigenetic therapy options for cancer...]. - Urologic Cancers

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Barber N, Ali A, editors. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; 2022 Sep 12. doi: 10.36255/exon-publications-urologic-cancers-bladder-cancer-epigenetics

Urologic Cancers [Internet].

Show details

Contents

Figure 3

Epigenetic therapy options for cancer treatment. Epidrugs can be used alone or in combination with the other treatments. Epigenome editing technologies are also emerging alternatives for cancer therapy. DNMTi, DNA methyltransferase inhibitors; EZH2i, EZH2 inhibitors; HATi, histone acetyltransferase inhibitors; HDACi, histone deacetylase inhibitors; HDMi, histone demethylase inhibitors; HMTi, histone methyltransferase inhibitors.

From: Chapter 5, Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer

Copyright: The Authors.
The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced.

Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/

Contents

Views

Cite this Page
Akman B, Erkek-Ozhan S. Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer. In: Barber N, Ali A, editors. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; 2022 Sep 12. Figure 3, [Epigenetic therapy options for cancer...]. doi: 10.36255/exon-publications-urologic-cancers-bladder-cancer-epigenetics
PDF version of this title (13M)